North America had the highest 12-month cancer prevalence rate in 2022. The 12-month prevalence rate for all cancers in North America as of this time was 595 per 100,000 population. This statistic displays 12-month cancer prevalence rates worldwide in 2022, by region.

In a recent report it was shown that the U.S. has the highest prevalence of diagnosed cancer cases among all adults, with around 9 percent of the adult population having some cancer diagnosis. Cancer is the second leading cause of death from chronic diseases worldwide after cardiovascular diseases.

Global cancer risks

Globally, cancer accounts for about 1 in every 6 deaths. Many cancer cases are caused by behavioral and dietary risks including tobacco, alcohol and physical inactivity. The prevalence of tobacco smoking is on the decline and is expected to decline further in the future. Smoking has been linked to lung cancer, other upper respiratory cancers and chronic obstructive pulmonary disease (COPD). Among other cancer risk factors, alcohol consumption has been linked to liver and colorectal cancers, as well as other non-communicable diseases. Many European countries have high rates of alcohol consumption.

Global cancer prevalence

Globally, trachea, bronchus and lung cancers are responsible for the most cancer deaths, followed by liver cancer. Lifestyle modification is one of the easiest ways people can reduce their risk of these types of cancer. Among all cancer patients globally, a majority had a history of alcohol consumption. Similarly, in China, EU5 and Russia, over a quarter of all cancer patients had a history of smoking.

In 2022, there were an estimated 2.48 million new cases of trachea, bronchus, and lung cancer worldwide. Breast cancer was the second most common cancer type at that time with around 2.3 million new cases worldwide.

Number of new cancer cases

Cancer can be caused by internal factors like genetics and mutations, as well as external factors such as smoking and radiation. It occurs in the presence of uncontrolled growth and spread of abnormal cells. However, many cancer cases could be prevented, for example, by omitting cigarette usage and heavy alcohol consumption. Risk of developing cancer tends to increase with age and is most common in older adults. Nevertheless, cancer can develop in individuals of any age. Cancer can be treated through surgery, radiation, and chemotherapy, among other methods.

In the United States, there will be an estimated two million new cancer cases and 611,720 deaths in 2024. Among U.S. men, prostate cancer and lung and bronchus cancers are the most common cancer types as of 2024, totaling an estimated 299,010 and 116,310 cases, respectively. In women, breast cancer and lung and bronchus cancer are the most common newly diagnosed types, totaling 310,720 and 118,270 cases, respectively.

United States US: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data was reported at 14.600 % in 2016. This records an increase from the previous number of 14.300 % for 2015. United States US: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data is updated yearly, averaging 14.600 % from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 18.000 % in 2000 and a record low of 14.300 % in 2015. United States US: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted Average;

US: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data was reported at 11.800 NA in 2016. This records an increase from the previous number of 11.600 NA for 2015. US: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data is updated yearly, averaging 11.800 NA from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 14.600 NA in 2000 and a record low of 11.600 NA in 2015. US: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United States – Table US.World Bank.WDI: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

In 2022, Australia had the fourth-highest total number of skin cancer cases worldwide and the highest age-standardized rate, with roughly 37 cases of skin cancer per 100,000 population. The graph illustrates the rate of skin cancer in the countries with the highest skin cancer rates worldwide in 2022.

Introduction

The Cancer Registry Software Market is projected to grow significantly, reaching a value of USD 205.7 million by 2033 from USD 78.6 million in 2023. This growth, driven by a compound annual growth rate (CAGR) of 10.1%, is attributed to the increasing global cancer incidence and rising demand for data management solutions in healthcare organizations. As cancer becomes a leading cause of death worldwide, healthcare providers are increasingly adopting cancer registry software to improve case tracking, surveillance, and treatment outcomes. The market is further supported by government initiatives aimed at enhancing national cancer registries.

Government regulations and national cancer registry programs are crucial drivers of this market's growth. Several countries are investing in enhancing their cancer surveillance systems to improve early detection and treatment outcomes. For instance, the U.S. Centers for Disease Control and Prevention (CDC) provides funding to support cancer registries. These initiatives not only encourage software adoption but also ensure adherence to state and federal reporting standards. As cancer data collection and analysis become a priority, cancer registry software is becoming indispensable to healthcare providers.

Technological advancements in Artificial Intelligence (AI) and Machine Learning (ML) are another key factor contributing to the market’s growth. The integration of these technologies into cancer registry software enables more efficient data collection, analysis, and reporting. AI and ML help identify trends, predict future cancer burdens, and support personalized treatment strategies. As these technologies evolve, their continued integration into registry software will drive further expansion, allowing healthcare professionals to make more informed decisions based on reliable data.

The growing need for real-time data for clinical decision-making and research is also fueling market growth. Cancer registry software plays a pivotal role in providing healthcare professionals with up-to-date information, crucial for both patient care and clinical research. Real-time cancer data is used to develop new therapies and improve treatment strategies. Researchers are increasingly relying on these databases to expedite breakthroughs in cancer treatment, which is contributing to the adoption of registry software solutions.

In summary, the Cancer Registry Software Market is experiencing rapid growth due to multiple factors, including the rising global cancer prevalence, government support, technological advancements, and the increasing demand for real-time cancer data. These elements are expected to continue driving market expansion as healthcare providers and governments prioritize cancer surveillance and management. The growing awareness of cancer's impact and the need for efficient data management are pivotal in sustaining the growth of this sector.

Snapshot img

Precision Pathology For Cancer Market Size 2025-2029

The global precision pathology for cancer market is projected to see substantial growth, with an estimated market size and a CAGR of 8.2% during the forecast period. Access detailed market insights upon report purchase. The precision pathology for cancer market is being drives by the rising incidence of cancer and the subsequent demand for enhanced personalized therapies. Digital pathology, boosted by AI and machine learning, enhances diagnostic accuracy, accelerates diagnosis rates, and facilitates therapeutic recommendations, thereby significantly contributing to market expansion. Technological advancements, such as AI tools that improve diagnostic precision and treatment planning in cancer care, are also expected to fuel market growth. The increasing investments in research and development activities will further contribute to market expansion.

To access the full market forecast and comprehensive analysis, Buy Now

How is this market segmented?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in USD bn for the period 2025-2029, as well as historical data from 2019-2024 for the following segments:

Product

  Consumables
  Instruments


Technology

  Next-Generation Sequencing (NGS)
  Molecular Diagnostics
  Digital Pathology
  Artificial Intelligence (AI) and Machine Learning (ML)
  Liquid Biopsies
  Imaging Technologies


Applications

  Breast Cancer
  Lung Cancer
  Colorectal Cancers
  Prostate Cancer
  Melanoma And Non-Melanoma Skin Cancers


End-use

  Hospitals
  Diagnostic Laboratories
  Research Institutes


APAC

  China
  India
  Japan
  Australia
  Rest of APAC

Europe


  Germany
  Spain
  Italy
  UK
  Rest of Europe

North America


  US
  Canada

South America & MEA


  Brazil
  UAE
  South Africa
  Others





End-use

  Hospitals: Hospitals are key end-users, utilizing precision pathology for in-house diagnostics and treatment planning.
  Research Institutes: Research institutes use precision pathology for cancer research and development of new diagnostic and therapeutic strategies.
  Diagnostic Laboratories: Diagnostic laboratories provide precision pathology services to hospitals and other healthcare providers.


Product

  Consumables: This segment includes antibodies, kits & reagents, and probes used in precision pathology, driven by the increasing volume of diagnostic tests.
  Instruments: This segment encompasses slide staining systems, tissue processing systems, and PCR instruments, crucial for accurate pathological analysis.


Technology

  Liquid Biopsies: Liquid biopsies offer non-invasive methods for detecting cancer biomarkers, aiding in early diagnosis and treatment monitoring.
  Digital Pathology: Digital pathology solutions improve diagnostic accuracy and support therapeutic recommendations, enhancing overall efficiency.
  Imaging Technologies: Imaging technologies like CT, MRI, and ultrasound provide detailed anatomical and functional information for cancer diagnosis and treatment.
  Molecular Diagnostics: Molecular diagnostics are used to detect specific biomarkers and genetic mutations in cancer cells, facilitating targeted therapies.
  Next-Generation Sequencing (NGS): NGS technology is vital for genetic profiling of tumors, enabling personalized treatment strategies.
  Artificial Intelligence (AI) and Machine Learning (ML): AI and ML algorithms aid in analyzing complex pathological data, improving diagnostic precision and treatment planning.


Applications

  Lung Cancer: Genetic profiling helps in selecting appropriate treatments for different types of lung cancer.
  Breast Cancer: Precision pathology is critical in identifying specific subtypes of breast cancer, guiding targeted therapies.
  Prostate Cancer: Precision diagnostics help in determining the aggressiveness of prostate cancer and guiding treatment decisions.
  Colorectal Cancers: Precision pathology aids in identifying genetic mutations that influence treatment response in colorectal cancer.
  Melanoma And Non-Melanoma Skin Cancers: Molecular analysis assists in identifying specific mutations in skin cancers, enabling personalized therapies.

Regional Analysis

APAC: The Asia-Pacific (APAC) region is expected to experience rapid growth in the precision pathology for cancer market, driven by increasing healthcare expenditure, a rising prevalence of cancer, and growing awareness of precision medicine. China and India are key markets in APAC, with significant investments in healthcare infrastructure and a large patient pool, making them major hubs for precision pathology services.
Europe: Europe holds a substantial share of the precision pathology for cancer market, characterized by advanced healthcare systems, a strong focus on research and development, and a high adoption rate of advanc

Bladder Cancer Market size was valued at USD 54.07 Billion in 2023 and is projected to reach USD 78.2 Billion by 2031, growing at a CAGR of 4.72% from 2024 to 2031.Key Market Drivers:• Bladder Cancer Incidence: The World Health Organization reports that the global incidence of bladder cancer is gradually increasing, with an estimated 549,000 new cases recorded in 2018. According to the American Cancer Society, approximately 84,430 new cases of bladder cancer will be detected in the United States alone by 2023.• Aging Population: The global population is aging, and bladder cancer is more common among older persons. The National Cancer Institute estimates that the median age at diagnosis for bladder cancer is 73 years. As the population ages, the chance of acquiring bladder cancer is predicted to rise, increasing the need for effective treatment and management alternatives.• Rising Risk Factors: Smoking, chemical exposure, and persistent bladder infections have all been related to an increased risk of getting bladder cancer. The Centers for Disease Control and Prevention (CDC) believes that smoking causes around 50% of bladder cancer cases in the United States.• Advancement in Diagnostic Techniques: Improved diagnostic procedures such as cystoscopy, urine cytology, and biomarker tests have allowed for earlier detection of bladder cancer, resulting in improved awareness and diagnosis rates. According to a study published in the Journal of the American Medical Association, the use of these advanced diagnostic technologies has led to an increase in the reported incidence of bladder cancer in recent years.

According to Cognitive Market Research , the global Targeted Cancer Drugs Market size will be XX million by 2033, whereas its compound annual growth rate (CAGR) will be XX% from 2025 to 2033. • North America held the largest share of the global Targeted Cancer Drugs market around XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2025 to 2033. • Asia Pacific held a market share of around XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2025 to 2033. • Europe accounted for a share of over XX% of the global market size of USD XX million. • The Latin American market is around XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2025 to 2033. • Middle East and Africa held the major market of around XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2025 to 2033. Market Dynamics of the Targeted Cancer Drugs Market

Key Drivers of the Targeted Cancer Drugs Market

Rising incidence of cancer enhances the targeted cancer drugs market growth

Tobacco use, high body mass index, alcohol usage, low intake of fruits and vegetables, and lack of physical activity are responsible for about one-third of cancer-related risk. Furthermore, one significant risk factor for lung cancer is air pollution. About 30% of cancer cases in low- and lower-middle-income nations are caused by diseases that cause cancer, such as hepatitis and the human papillomavirus (HPV). How frequently a cancer arises (incidence) and how long people typically live after being diagnosed (survival) are the two factors that determine cancer prevalence. This indicates that the most prevalent malignancies with the longest survival have the highest prevalence counts. Compared to a less common cancer with a longer survival, a common cancer with a shorter survival may have a lower prevalence count. For instance, according to the American Cancer Society 2023, non-Hodgkin lymphoma, a less common cancer, has a higher prevalence rate than lung cancer, despite lung cancer being one of the most common malignancies in the US. There are more persons living after a diagnosis of non-Hodgkin lymphoma than after a diagnostic of lung cancer because those with non-Hodgkin lymphoma have a higher chance of surviving longer than those with lung cancer. There were 1,777,566 new cases of cancer reported in the US in 2021. An estimated 608,366 Americans lost their lives to cancer in 2022. https://www.cdc.gov/cancer/data/index.html In the twenty-first century, cancer is a significant social, public health, and economic issue, accounting for about one in six fatalities (16.8%) and one in four deaths (22.8%) from noncommunicable diseases (NCDs) globally. Three out of ten premature deaths worldwide are caused by NCDs (30.3% in people aged 30 to 69), and in 177 out of 183 nations, it ranks among the top three causes of death for this age group. Apart from being a significant hindrance to extending life expectancy, cancer is linked to significant societal and macroeconomic expenses, which differ in extent depending on the type of cancer, location, and gender. For instance, according to International Agency for Research on Cancer in 2022, there were about 20 million new cases of cancer, including nonmelanoma skin cancers (NMSCs), and 9.7 million cancer-related deaths. According to estimates, one in five men and women will get cancer at some point in their lives, while one in nine men and one in twelve women will pass away from the disease. With about 2.5 million new cases, or one in eight cancers worldwide (12.4% of all cancers), lung cancer was the most commonly diagnosed cancer in 2022. It was followed by stomach (4.9%), colorectum (9.6%), prostate (7.3%), and female breast (11.6%) cancers. With an anticipated 1.8 million deaths (18.7%), lung cancer was also the most common cause of cancer-related mortality. Colorectal (9.3%), liver (7.8%), female breast (6.9%), and stomach (6.8%) cancers were next in line. The two most common cancers in both men and women were lung and breast cancer. https://acsjournals.onlinelibrary.wile...

The North America cancer therapy market, valued at approximately $XX million in 2025, is projected to experience robust growth, exhibiting a compound annual growth rate (CAGR) of 8.10% from 2025 to 2033. This expansion is driven by several key factors. Rising cancer incidence rates across the region, coupled with an aging population, significantly fuels demand for effective therapies. Advances in immunotherapy, targeted therapies, and other innovative treatment modalities are improving patient outcomes and extending life expectancy, thereby bolstering market growth. Furthermore, increasing healthcare expenditure and the rising adoption of advanced diagnostic techniques contribute to the market's expansion. The market segmentation reveals strong growth across various cancer types, with blood cancers, breast cancer, and prostate cancer representing significant segments. The dominance of hospitals and specialty clinics as end-users underscores the importance of established healthcare infrastructure in delivering cancer therapies. However, high treatment costs and potential side effects associated with certain therapies may pose challenges to market expansion, although the ongoing development of less toxic and more targeted treatments is expected to mitigate this restraint. The competitive landscape is characterized by the presence of major pharmaceutical companies actively involved in research and development, driving innovation and competition. North America, with its robust healthcare infrastructure and high per capita healthcare spending, maintains a significant share of the global cancer therapy market. The market's growth trajectory suggests a significant expansion throughout the forecast period, driven by continued innovation in treatment modalities and the growing awareness of cancer prevention and early detection. The dominance of specific treatment types, like immunotherapy and targeted therapies, reflects the shift towards personalized medicine. Ongoing clinical trials and research efforts focusing on novel therapeutic approaches are further expected to drive market growth. Regulatory approvals of new therapies, alongside robust investment in R&D, will play a critical role in shaping the market's future landscape. The competitive dynamics within the industry suggest a continuous effort to enhance treatment efficacy and reduce treatment-related adverse effects, leading to improved patient care and market expansion. The market's regional distribution reflects the concentration of advanced medical facilities and a high prevalence of cancer cases in North America, thus contributing to its leadership in this therapeutic area. North America Cancer Therapy Market: A Comprehensive Report (2019-2033) This comprehensive report provides an in-depth analysis of the North America cancer therapy market, encompassing market dynamics, industry trends, leading segments, key players, and future outlook. The study period covers 2019-2033, with a base year of 2025 and a forecast period of 2025-2033. The market is segmented by treatment type, cancer type, and end-user, offering a granular understanding of this vital sector. Projected market value for 2025 is estimated at xx Million. This report is an invaluable resource for industry stakeholders, investors, and researchers seeking actionable insights into this rapidly evolving market. Recent developments include: In September 2022, Eli Lilly and Company announced that the United States Food and Drug Administration (FDA) has approved Retevmo (selpercatinib, 40 mg & 80 mg capsules) for adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion that has progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options., In August 2022, the United States Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion for the treatment of patients with unresectable (unable to be removed) or metastatic (spread to other parts of the body) HER2-low breast cancer.. Key drivers for this market are: Rising Prevalence of Cancer, Strong R&D Initiatives from Key Players and the Government; Growing Government Initiatives for Cancer Awareness. Potential restraints include: Fluctuation in Reimbursement Policies, High Cost of Cancer Therapies. Notable trends are: The Target Therapy Segment is Expected to show the Fastest Growth During the Forecast Period.

The global cancer early detection market, valued at $241 million in 2025, is projected to experience robust growth, driven by a 7.3% CAGR from 2025 to 2033. This expansion is fueled by several key factors. Firstly, the rising incidence of cancers like colorectal, liver, and lung cancer globally necessitates advanced diagnostic tools for early detection and improved patient outcomes. Secondly, technological advancements in areas such as liquid biopsies, molecular diagnostics, and AI-powered image analysis are significantly enhancing the accuracy and efficiency of early detection methods. This leads to earlier diagnosis, allowing for less invasive treatments and improved survival rates. Furthermore, increasing healthcare expenditure and greater awareness among the public about the benefits of early cancer screening are contributing to market growth. However, factors such as high costs associated with advanced diagnostic tests and the need for specialized expertise to interpret results pose challenges to market penetration, particularly in low- and middle-income countries. The market segmentation reveals a significant demand across hospitals and medical centers, with colorectal, liver, and lung cancer testing leading the application-based segments. Key players, including Exact Sciences, Grail, and others, are actively investing in R&D and strategic partnerships to expand their market share and introduce innovative solutions. The geographical landscape shows strong growth potential across North America and Europe, driven by advanced healthcare infrastructure and increased screening initiatives, while Asia-Pacific is expected to witness significant growth in the coming years due to increasing cancer incidence and rising disposable incomes. The competitive landscape is characterized by both established players and emerging companies vying for market share. The ongoing innovations in cancer detection technologies are driving competition and shaping the future of the market. Future growth will depend on continued technological advancements, regulatory approvals for newer diagnostic tools, and strategic initiatives to address accessibility and affordability issues in underserved regions. The market's success hinges on collaboration between healthcare professionals, researchers, and policymakers to improve early detection rates and ultimately improve cancer survival rates globally. A focus on public awareness campaigns and improved reimbursement policies can further accelerate market growth and ensure equitable access to life-saving technologies.

Snapshot img

Cancer Immunotherapy Market Size 2024-2028

The cancer immunotherapy market size is forecast to increase by USD 45.5 billion at a CAGR of 8.1% between 2023 and 2028. The market is witnessing substantial growth due to the high prevalence of cancer, increasing consumer awareness towards advanced treatment options, and a robust Research and Development (R&D) pipeline focusing on monoclonal antibodies. This expansion is primarily driven by the demand for innovative solutions, advancements in technology, and evolving consumer preferences. As the industry evolves, there is a transition towards more efficient systems, improved accessibility, and higher industry standards. Companies in this sector are adapting their strategies to align with these trends, prioritizing sustainability and operational efficiency to maintain a competitive edge. The market's future direction is influenced by these factors, ensuring long-term growth and expansion. The growing demand for advanced cancer treatment solutions continues to fuel market evolution, with a focus on delivering effective, accessible, and cost-efficient therapies.

What will be the size of the market during the forecast period?

Request Free Sample

Cancer Immunotherapy Market Segmentation

The cancer immunotherapy market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.

Type

  Monoclonal antibodies
  Check point inhibitors and immunomodulators
  Cancer vaccines


Application

  Lung cancer
  Breast cancer
  Colorectal cancer
  Others


Geography

  North America

    Canada
    US


  Europe

    Germany
    France


  Asia

    China


  Rest of World (ROW)

Which is the largest segment driving market growth?

The monoclonal antibodies segment is estimated to witness significant growth during the forecast period.

Monoclonal antibodies and checkpoint inhibitors have emerged as key players In the cancer treatment landscape. These man-made proteins, designed to mimic the immune system's response, are used to target specific cancer cells, such as those expressing human epidermal growth factor receptor 2 in breast cancer, treated with trastuzumab. Lung, colorectal, melanoma, breast, head & neck, and prostate cancers are among the many types treated with these agents. Hospitals, clinics, and cancer research centers administer these therapies, which include cancer vaccines, immunomodulators, target therapies, and traditional chemotherapies or radiation therapy. Immunotherapies, such as CAR-T cell therapy and checkpoint inhibitors, have revolutionized cancer treatment, offering improved patient outcomes.

Financial burden remains a concern, with new treatments like quizartinib for acute myeloid leukemia and FLT3 inhibitors under development. Bioinformatics tools aid In the discovery and development of these therapies. Oncolytic viral therapies, such as talimogene laherparepvec and sipuleucel-T, and repotrectinib, a selective TRK inhibitor, are also gaining popularity. The healthcare industry, including hospital pharmacies and online pharmacies, plays a crucial role In the distribution and administration of these treatments.

Get a glance at the market share of various regions. Download the PDF Sample

The Monoclonal antibodies segment was valued at USD 36.30 billion in 2018 and showed a gradual increase during the forecast period.

Which region is leading the market?

North America is estimated to contribute 43% to the growth of the global market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.The North American region leads The market due to substantial investments In the oncology sector, particularly In the US. With a significant presence of pharmaceutical companies, the US dominates the regional market and contributes significantly to its global share. In the US, cancer is a prevalent chronic disease, with approximately 436 new cases reported per 100,000 population and 156 deaths In the same year. Immunotherapies, including monoclonal antibodies, checkpoint inhibitors, and cancer vaccines, are increasingly used for treating various types of cancer, such as lung, breast, colorectal, melanoma, head & neck, prostate, and others. Hospitals, clinics, and cancer research centers are key end-users of these therapies.

Immunomodulators, target therapies, traditional chemotherapies, and radiation therapies are also used in combination with immunotherapies. Financial burden remains a challenge for cancer patients, with treatments like quizartinib for acute myeloid leukemia and FLT3 inhibitors requiring significant investment. Inn

Introduction

Global AI in Cancer Diagnosis Market is growing rapidly. It is expected to reach USD 1943.6 million by 2033, up from USD 175.3 million in 2023. This represents a compound annual growth rate (CAGR) of 27.2% from 2024 to 2033. With a market share over 58.4%, North America held a strong lead in 2023, reaching USD 102.3 Million in revenue.

This expansion highlights the pivotal role of artificial intelligence (AI) in transforming cancer diagnostics, driven by the growing incidence of cancer and the urgent need for precise and efficient diagnostic methods.

Key drivers of this market growth include the escalating global cancer rates, which demand advanced solutions for early detection and accurate diagnosis. North America is anticipated to maintain its market dominance, due to its high cancer incidence and the substantial adoption of AI technologies in healthcare diagnostics. AI integration significantly boosts the accuracy, speed, and efficiency of cancer diagnosis, enabling timely treatment decisions and personalized care.

Recent developments in the sector emphasize its dynamic nature and potential for innovation. Strategic partnerships between leading healthcare providers and technology companies are enhancing AI-driven diagnostic tools, which help clinicians deliver more effective care. These collaborations are crucial for developing and refining AI applications that aim to improve diagnostic precision, minimize delays, and ultimately enhance patient outcomes.

However, the market faces challenges such as the need for extensive data sets to train AI algorithms, high integration costs, and complex regulatory environments. Despite these obstacles, ongoing advancements in AI technology and an increased focus on personalized medicine are expected to promote the widespread adoption of AI in cancer diagnosis. This signifies a promising new phase of innovation and improved care within the oncology sector.

The AI in cancer diagnosis market stands at a critical point, with significant growth opportunities and the potential to profoundly impact healthcare delivery. Marked by technological progress, strategic alliances, and a dedicated focus on enhancing diagnostic processes, the sector is poised to contribute to better patient outcomes and more efficient healthcare systems.

The global Cancer Registry Software market, valued at $118.11 million in 2025, is projected to experience robust growth, driven by a Compound Annual Growth Rate (CAGR) of 12.75% from 2025 to 2033. This expansion is fueled by several key factors. The increasing prevalence of cancer globally necessitates efficient and comprehensive cancer registries for epidemiological research, public health initiatives, and improved patient care. Government mandates and funding for cancer control programs are significantly boosting market adoption, particularly in North America and Europe. Furthermore, technological advancements in data analytics, cloud computing, and artificial intelligence are enhancing the capabilities of cancer registry software, leading to improved data management, analysis, and reporting. The rising demand for interoperability between different healthcare systems and the need for real-time data access further contribute to market growth. Pharmaceutical and biotech companies are increasingly leveraging cancer registry data for clinical trials and drug development, creating another significant revenue stream for software providers. The market is segmented by deployment (government, pharma/biotech, hospitals, private payers, research institutes) and geography, with North America currently holding a dominant market share due to advanced healthcare infrastructure and high cancer incidence rates. However, market growth faces certain challenges. High implementation costs and the need for specialized expertise can be barriers to entry for smaller hospitals and clinics. Data security and privacy concerns surrounding sensitive patient information require robust security measures, potentially adding to costs. The complexity of integrating cancer registry software with existing healthcare information systems can also hinder widespread adoption. Despite these restraints, the long-term outlook for the Cancer Registry Software market remains positive, driven by the continued rise in cancer cases, technological innovations, and increasing government support for cancer control initiatives. Competition is expected to intensify, with established players and emerging tech companies vying for market share. Strategic partnerships and mergers and acquisitions are likely to shape the industry landscape in the coming years.

As of 2021, non-Hispanic white people in the United States had the highest incidence rates of skin cancer among all races and ethnicities. Skin cancer is one of the most commonly occurring cancers in the world. Furthermore, the United States is among the countries with the highest rates of skin cancer worldwide. Skin cancer in the U.S. There are a few different types of skin cancer and some are more deadly than others. Basal and squamous skin cancers are more common and less dangerous than melanomas. Among U.S. residents, skin cancer has been demonstrated to be more prevalent among men than women. Skin cancer is also more prevalent among older adults. With treatment and early detection, skin cancers have a high survival rate. Fortunately, in recent years the U.S. has seen a reduction in the rate of death from melanoma. Skin cancer prevention Avoiding and protecting exposed skin from the sun (and other sources of UV light) is the primary means of preventing skin cancer. However, a survey of U.S. adults from 2024 found that around a third never used sunscreen.

BackgroundColorectal cancer (CRC) incidence rates have increased in younger individuals worldwide. We examined the most recent early- and late-onset CRC rates for the US.MethodsAge-standardized incidence rates (ASIR, per 100,000) of CRC were calculated using the US Cancer Statistics Database’s high-quality population-based cancer registry data from the entire US population. Results were cross-classified by age (20-49 [early-onset] and 50-74 years [late-onset]), race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic, American Indian/Alaskan Native, Asian/Pacific Islander), sex, anatomic location (proximal, distal, rectal), and histology (adenocarcinoma, neuroendocrine).ResultsDuring 2001 through 2018, early-onset CRC rates significantly increased among American Indians/Alaskan Natives, Hispanics, and Whites. Compared to Whites, early-onset CRC rates are now 21% higher in American Indians/Alaskan Natives and 6% higher in Blacks. Rates of early-onset colorectal neuroendocrine tumors have increased in Whites, Blacks, and Hispanics; early-onset colorectal neuroendocrine tumor rates are 2-times higher in Blacks compared to Whites. Late-onset colorectal adenocarcinoma rates are decreasing, while late-onset colorectal neuroendocrine tumor rates are increasing, in all racial/ethnic groups. Late-onset CRC rates remain 29% higher in Blacks and 15% higher in American Indians/Alaskan Natives compared to Whites. Overall, CRC incidence was higher in men than women, but incidence of early-onset distal colon cancer was higher in women.ConclusionsThe early-onset CRC disparity between Blacks and Whites has decreased, due to increasing rates in Whites—rates in Blacks have remained stable. However, rates of colorectal neuroendocrine tumors are increasing in Blacks. Blacks and American Indians/Alaskan Natives have the highest rates of both early- and late-onset CRC.ImpactOngoing prevention efforts must ensure access to and uptake of CRC screening for Blacks and American Indians/Alaskan Natives.

The global cancer treatment market, valued at $220.24 billion in 2025, is projected to experience robust growth, driven by a rising global cancer incidence, advancements in treatment modalities, and an aging population. The Compound Annual Growth Rate (CAGR) of 10.64% from 2025 to 2033 signifies significant market expansion. Key drivers include the increasing prevalence of various cancer types like blood cancers, breast cancer, and lung cancer, coupled with the development and adoption of innovative therapies such as targeted therapy and immunotherapy. These advanced therapies offer improved efficacy and survival rates compared to traditional chemotherapy, further fueling market growth. However, high treatment costs and the potential for adverse effects associated with certain therapies pose significant restraints. The market is segmented by therapy type (chemotherapy, targeted therapy, immunotherapy, hormonal therapy, and others), cancer type (blood, breast, prostate, gastrointestinal, gynecologic, respiratory/lung, and others), and end-user (hospitals, specialty clinics, and cancer centers). The regional landscape showcases North America as a dominant market share holder, fueled by high healthcare expenditure and advanced infrastructure, followed by Europe and Asia Pacific. The competitive landscape is characterized by the presence of major pharmaceutical companies actively involved in research and development, leading to continuous innovation in cancer therapies. The forecast period (2025-2033) anticipates sustained growth across all segments. The increasing affordability and accessibility of advanced therapies in emerging markets like Asia Pacific and Latin America are expected to boost market expansion in these regions. However, regulatory hurdles and reimbursement challenges in certain countries might hinder market growth to some extent. Further research into personalized medicine and cancer prevention strategies will continue to influence the market dynamics in the coming years. The focus on improving patient outcomes and reducing treatment-related side effects will likely drive innovation and adoption of novel cancer therapies in the future. Companies are investing heavily in R&D, leading to a pipeline of promising new drugs and treatment approaches. This constant innovation ensures the long-term growth and evolution of the cancer treatment market. Recent developments include: In May 2023, Genmab A/S received USFDA approval for its T-cell engaging bispecific antibody, EPKINLY (epcoritamab-bysp), which was intended for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in adult patients., In April 2023, Genentech, a member of the Roche Group, received USFDA approval for its cancer therapy drug, Polivy (polatuzumab vedotin-piiq) in combination with Rituxan (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP). The drug is intended for the treatment of previously untreated diffuse large B-cell lymphoma (DLBCL) in adult patients., In April 2023, Gamida Cell Ltd received USFDA approval for its allogeneic cell therapy, Omisirge (omidubicel-onlv), intended for adult and pediatric patients 12 years and older with hematologic malignancies.. Key drivers for this market are: Increasing Patient Assistance Programs (PAPs) and Rising Demand for Personalized Medicine, Growing Government Initiatives for Cancer Awareness; Rising Prevalence of Cancer Worldwide; Strong R&D Initiatives from Key Players. Potential restraints include: Fluctuation in Reimbursement Policies, High Cost of Cancer Therapies. Notable trends are: The Targeted Therapy Segment is Expected to Witness Significant Growth during the the Forecast Period.